How does dupixent work for eosinophilic esophagitis?

How does dupixent block the signals that drive eosinophilic esophagitis?

Dupixent is a monoclonal antibody that attaches to the IL-4 receptor alpha and prevents both IL-4 and IL-13 from binding. In eosinophilic esophagitis these two cytokines recruit eosinophils, stimulate mucus production, and thicken the esophageal wall, so interrupting the pathway reduces inflammation and allows the lining to heal. [1]

What clinical results led to FDA approval for this use?

In two randomized trials, patients on 300 mg weekly Dupixent reached histologic remission (fewer than 6 eosinophils per high-power field) at rates of 60 % and 59 %, compared with 5–6 % on placebo. Symptom scores for dysphagia and food impaction also fell significantly, prompting approval in May 2022. [1]

How long does it take to see improvement?

Histologic changes can be measured at 12 weeks, yet most patients notice easier swallowing between 4 and 8 weeks after starting weekly injections. Continued dosing maintains the response; stopping the drug leads to recurrence within months. [1]

What side effects do patients report most often?

Injection-site reactions occur in about 8 % of users. Conjunctivitis and joint pain each affect roughly 2 %. Serious adverse events remain rare, but clinicians monitor for allergic reactions and herpes infections. [1]

Can patients switch from steroids or elimination diets to Dupixent?

Many adults and adolescents who have incomplete relief on topical steroids or find elimination diets too restrictive start Dupixent as monotherapy. Those who respond often taper steroids under medical supervision while continuing the biologic. [1]

When does the main patent for Dupixent expire?

The key U.S. composition-of-matter patent for dupilumab expires in 2031, with potential pediatric extensions pushing protection into the mid-2030s. Biosimilar entry is therefore unlikely before the early 2030s. [2]

What other IL-4/IL-13 inhibitors are in development?

Cendakimab and several oral JAK inhibitors are being tested for eosinophilic esophagitis, but none have reached phase 3 completion yet. Dupixent remains the only approved agent in its class for this indication. [1]

[1] https://www.drugpatentwatch.com/drug/dupixent
[2] https://www.drugpatentwatch.com/drug/dupixent